Two recent well-designed, double-blind, controlled trials showed no benefit for combined oral oral EPA (Eicosa Pentaenoic Acid) and DHA (Docosa Hexaenoic Acid) supplement (prominently found in seafood, especially fatty fish) for reducing the risk of cardiovascular events compared with corn-oil placebo. The first trial, the STRENGTH trial, was funded by AstraZeneca and conducted Cleveland Clinic and international researchers, and published in the Journal of the American Medical Association (Dec. 8, 2020). The second trial, the OMEMI trial, was a foundation-funded trial conducted by Norwegian researchers and published in Circulation (Feb. 9, 2021).
The STRENGTH trial had 13,100 adults enrolled who had, or were at high risk of, cardiovascular disease with high triglyceride or low high-density lipoprotein cholesterol levels and had already taken statin drugs to lower their cholesterol levels for four weeks. They assigned randomly one-half of these subjects to receive a high daily dose (4 grams) of combined EPA and DHA supplements. The other half received a corn-oil placebo. After 3.5 years of follow-up, there was no difference in the number of serious cardiovascular events. If anything, new cases of atrial fibrillation as well as gastrointestinal adverse events were somewhat higher in the EPA-DHAA group than in the control group.
The OMEMI trial had more than 1,000 older adults enrolled who had suffered a heart attack 2 to 8 weeks before enrollment. The researchers randomly assigned half of the subjects to receive 1.8 grams of a combined EPA and DHA supplement and the other half to receive a corn-oil placebo every day. After two years of follow-up, there was no difference in the two groups in the number of serious cardiovascular events. If anything, the new-onset of atrial fibrillation was higher in the EPA-DHA group when compared to the placebo group.
The body’s requirement for Omega-3 Fatty Acids is quite low and can be easily met by relying on plant-based ALA l(Alpha-Linolenic Acid) as found in chia seeds, flaxseeds, soybeans, walnuts, and hemp seeds. Some 15% of ALA can be converted by the liver into EPA and DHA, an amount that is sufficient to meet the body’s requirement for optimal function.